COX-2 inhibitor safety in the workers' compensation market.
Foster
Matthew
M
Kendall
Ralph
R
Todd
Mary
M
D000329:Advertising; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004346:Drug Information Services; D011307:Drug Prescriptions; D004363:Drug Utilization / Q000639:trends; D019981:Health Care Sector; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D033181:Information Dissemination; D008565:Membrane Proteins; D009784:Occupational Diseases / Q000188:drug therapy; D018579:Patient Selection; D010818:Practice Patterns, Physicians' / Q000639:trends; D011358:Product Surveillance, Postmarketing; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects*; D012449:Safety; D020521:Stroke / Q000139:chemically induced; D014481:United States; D014486:United States Food and Drug Administration; D014942:Workers' Compensation
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases